A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer (Q36201492)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

anaplastic thyroid cancer

7 February 2020

main subject

phase II clinical trial

0 references

1 reference

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

19

Charles Erlichman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1

Keith C Bible

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

5

Julian R Molina

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

2

Vera J Suman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Michael E Menefee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Robert C Smallridge

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

William J Maples

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Nina J Karlin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Anne M Traynor

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Priya Kumar

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Boon Cher Goh

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Ayoko R Bossou

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Crescent R Isham

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Kevin P Webster

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Andrea K Kukla

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Carolyn Bieber

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Jill K Burton

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Pamela Harris

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Mayo Phase 2 Consortium

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Mayo Clinic Endocrine Malignances Disease Oriented Group

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

English

0 references

publication date

6 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

The Journal of Clinical Endocrinology and Metabolism

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

3179-3184

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

7 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

Anaplastic thyroid carcinoma: pathogenesis and emerging therapies

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

Phase II trial of sorafenib in metastatic thyroid cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

Phase II trial of sorafenib in advanced thyroid cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

A three-outcome design for phase II clinical trials.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

Enhanced Survival in Locoregionally Confined Anaplastic Thyroid Carcinoma: A Single-Institution Experience Using Aggressive Multimodal Therapy

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

A phase II study of imatinib in patients with advanced anaplastic thyroid cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

A case of anaplastic thyroid cancer with long-term survival.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

The feasibility study of docetaxel in patients with anaplastic thyroid cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3431569

Anaplastic thyroid carcinoma: a 50-year experience at a single institution

22 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22774206

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1210/JC.2012-1520

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22774206%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

PubMed publication ID

22774206

1 reference